Article
Cereblon-based Bifunctional Degrader of SOS1, BTX-6654, Targets Multiple KRAS Mutations and Inhibits Tumor Growth.
Molecular cancer therapeutics - 2 Apr 2024
Begovich Kyle, Schoolmeesters Angela, Rajapakse Navin, Martinez-Terroba Elena, Kumar Maneesh, Shakya Arvind, Lai Chon, Greene Steven, Whitefield Brandon, Okano Akinori, Mali Venkat, Huang Shenlin, Chourasia Aparajita H, Fung Leah
Abstract excerpt
Mutations within the oncogene KRAS drive an estimated 25% of all cancers. Only allele-specific KRAS G12C inhibitors are currently available and are associated with the emergence of acquired resistance, partly due to upstream pathway reactivation. Given its upstream role in the activation of KRAS, son of sevenless homolog 1 (SOS1), has emerged as an attractive therapeutic target. Agents that target SOS1 for...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.